Adil Aftab: Acute VTE Treatment and Anticoagulation Considerations in Renal Dysfunction
Adil Aftab, Postgraduate Trainee at People’s University of Medical and Health Sciences for Women, Nawabshah, shared a post on LinkedIn:
“Acute DVT or PE (VTE) Treatment, Anticoagulation and Renal Function
Anticoagulation is the cornerstone of acute venous thromboembolism management. Choosing the right agent requires careful consideration of renal function, bleeding risk, drug interactions, clinical stability, and patient preference.
This quick reference chart highlights commonly used options including Apixaban, Rivaroxaban, Edoxaban, Dabigatran, LMWH, and UFH, with important renal function considerations.
Key clinical points:
- Use Cockcroft Gault CrCl when making anticoagulant dosing decisions.
- Reassess renal function regularly.
- UFH is often preferred when renal function is unstable or bleeding risk is high.
- DOAC selection should be individualized according to renal function and clinical circumstances.
- Always assess contraindications and situations requiring temporary interruption of anticoagulation.
Continuous learning and evidence based prescribing are essential for safe VTE management.”
Stay updated with Hemostasis Today.
-
Sep 10, 2026, 14:21Seth Green: Testosterone Replacement Therapy and VTE Risk When Is the Risk Highest
-
Sep 10, 2026, 13:56Sumyea Kabir: Wet Hijama and Blood Donation Why Deferral Matters
-
Sep 10, 2026, 11:56William Pao: Celebrating a Landmark Breakthrough in Hemophilia Care
-
Sep 10, 2026, 11:25Andreas Glenthøj: New Sickle Cell Trait Data in UpToDate
-
Sep 10, 2026, 10:53A New Era of Hemophilia Screening and Diagnosis in Women and Girls – ISTH
-
Sep 10, 2026, 10:03Investing in Youth, Transforming Hemophilia Care – WFH
-
Sep 10, 2026, 09:51Ronke Oke BEM: 20 Years of Newborn Sickle Cell Screening in England
-
Sep 10, 2026, 09:41Seunghwan Song: Hemlibra and the Science That Changed Hemophilia A Care
-
Sep 10, 2026, 09:20Mark Dawson: A Radical Rethink of Hemophilia Treatment